Evommune, Inc. (EVMN) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-2667.3%

-$156.09

vs $6.08 price

Levered DCF

-$268.07

After debt service

Piotroski score

4 / 9

Average

Altman Z-score

4.4

Safe zone

Rating

C+

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023
P/E	-1.53×	-8.91×	-17.9×
P/B	0.51×	-4.22×	-7.83×
P/S	8.08×	86.92×	121.69×
EV / EBITDA	-0.79×	-12×	-22.13×
Gross margin	100.0%	81.6%	80.0%
Operating margin	-623.6%	-1000.2%	-757.0%
Net margin	-529.8%	-954.4%	-681.1%
Current ratio	8.57×	2.64×	11.67×
Debt / equity	0.01×	-1.34×	-1.94×
Interest coverage	0×	-2,059.21×	-652.59×
Dividend yield	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023
Return on equity	-33.5%	46.3%	43.8%
Return on invested capital	-39.1%	-142.6%	-49.7%
Return on assets	-30.6%	-87.8%	-41.4%
Free cash flow yield	-73.0%	-9.6%	-4.9%
Earnings yield	-65.6%	-11.0%	-5.6%
Enterprise value	$62.7M	$785.5M	$730.1M
Net debt / EBITDA	0.53×	-2.7×	-3.69×
Cash conversion cycle (days)	0	-2,344	-642